Full Press Release Details
Home
Pipeline
Team
Research
NEWS
INVESTORS
Careers
Contact
Array - March 25, 2026
An oral allopregnanolone prodrug bypasses liver metabolism via lymphatic transport enabling bioavailability in animals and humans
SPTX Positive Sentiment
An oral allopregnanolone prodrug bypasses liver metabolism via lymphatic transport enabling bioavailability in animals and humans
Key Takeaway: The article discusses a new oral allopregnanolone prodrug that successfully bypasses liver metabolism through lymphatic transport. This advancement significantly enhances bioavailability in both animal models and human subjects. The innovative approach may lead to improved therapeutic outcomes for patients requiring this treatment.
Market Sentiment Analysis
POSITIVE FACTORS
- The prodrug demonstrates improved bioavailability in both animals and humans.
- Bypassing liver metabolism could enhance therapeutic efficacy.
- Innovative lymphatic transport mechanism shows promise for oral administration.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~12 mo
Low dilution risk
Lead asset
SPT-300
Phase 2 · Major Depressive Disorder (MDD)
Frequently Asked Questions
What is the significance of the allopregnanolone prodrug?
The prodrug enhances bioavailability by bypassing liver metabolism.
How does the prodrug achieve improved bioavailability?
It utilizes lymphatic transport to bypass liver metabolism.
In which subjects was the prodrug tested?
The prodrug was tested in both animals and humans.
What potential benefits does this prodrug offer?
It may lead to improved therapeutic efficacy for patients.